Evidence map›Paper›PMID 34370591›Full record

ReviewCannabis and cannabinoid research2022

Cannabis as an Anticancer Agent: A Review of Clinical Data and Assessment of Case Reports.

Jordan Guggisberg, Megan Schumacher, Grace Gilmore, Dylan M Zylla

Open access · greenAbstract readCase ReportsReview
In one paragraph

Review in Cannabis and cannabinoid research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Guideline
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Current and Potential Use of Biologically Active Compounds Derived fromInternational journal of molecular sciences · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Medicinal cannabis - has it found a place in palliative care?Palliative care and social practice · 2024
    Article
  13. Review
  14. Review
  15. Should oncologists trust cannabinoids?Frontiers in pharmacology · 2023
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jordan GuggisbergThe Cancer Research Center, HealthPartners/Park Nicollet, Minneapolis, Minnesota, USA.
Megan SchumacherThe Cancer Research Center, HealthPartners/Park Nicollet, Minneapolis, Minnesota, USA.
Grace GilmoreThe Cancer Research Center, HealthPartners/Park Nicollet, Minneapolis, Minnesota, USA.
Dylan M ZyllaThe Cancer Research Center, HealthPartners/Park Nicollet, Minneapolis, Minnesota, USA.ORCID 0000-0003-1726-3715
Park Nicollet Health Services · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsCannabidiolCannabinoidsCannabisHallucinogensMedical MarijuanaNeoplasmsAnalgesicsCannabinoid Receptor AgonistsChildHumansAnalgesicsAntineoplastic AgentsCannabidiolCannabinoid Receptor AgonistsCannabinoidsHallucinogensMedical Marijuanaantineoplasticcancercannabismarijuana

Identifiers

PMID34370591
PMCPMC8864433
OpenAlexW3187346042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.